Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

@article{Liu2017RepigmentationIV,
  title={Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.},
  author={Lucy Yichu Liu and James P. Strassner and Maggi A Refat and John E Harris and Brett Andrew King},
  journal={Journal of the American Academy of Dermatology},
  year={2017},
  volume={77 4},
  pages={675-682.e1}
}
BACKGROUND Vitiligo is an autoimmune disease in which cutaneous depigmentation occurs. Existing therapies are often inadequate. Prior reports have shown benefit of the Janus kinase (JAK) inhibitors. OBJECTIVE To evaluate the efficacy of the JAK 1/3 inhibitor tofacitinib in the treatment of vitiligo. METHOD This is a retrospective case series of 10 consecutive patients with vitiligo treated with tofacitinib. Severity of disease was assessed by body surface area of depigmentation. RESULTS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 30 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
2 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-2 of 2 extracted citations

Similar Papers

Loading similar papers…